Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

Key points – With 5-year median follow-up, continuous single-agent ibrutinib therapy was well tolerated with deepening of response. Previously untreated patients, even those with TP53 aberration, achieved durable responses.